Shire plc Shire Plc : Notice Of Results

Features Dow Jones Newswires

TIDMSHP

Continue Reading Below

Shire to announce third quarter 2017 results

Dublin, Ireland - October 12, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG),

will announce third quarter 2017 earnings on Friday October 27, 2017.

Results press release will be issued at: 12:00 BST / 07:00 EDT

Investor conference call time: 14:00 BST / 09:00 EDT

Continue Reading Below

Live conference call for investors:

Flemming Ornskov, MD, Chief Executive Officer, Jeff Poulton, Chief

Financial Officer and Matt Walker, Head of Technical Operations will

host the investor and analyst conference call at

9:00 EDT / 14:00 BST.

The details of the conference call are as follows:

UK dial in: 0808 237 0030 or 020 3139 4830

US dial in: 1 866 928 7517 or 1 718 873 9077

International Click here:

Access http://events.arkadin.com/ev/docs/NE_FEL_Events_International_Acc

Numbers: ess_List.pdf

Password/Conf 31097524#

ID:

Live Webcast: Click here

http://investors.shire.com/presentations-and-reports/quarterly-re

sults-and-presentations

Replay:

A replay of the presentation will be available for two weeks by phone

and by webcast for three months. Replay information can be found on the

Investor Relations section of Shire's website at

http://investors.shire.com/.

For further information please contact:

Investor Relations

Ian Karp ikarp@shire.com +1 781 482 9018

Robert Coates rcoates@shire.com +44 203 5490874

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving

people with rare diseases and other highly specialized conditions. We

strive to develop best-in-class products, many of which are available in

more than 100 countries, across core therapeutic areas including

Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage

Disorders, Gastrointestinal / Internal Medicine / Endocrine and

Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop

and deliver breakthrough therapies for the hundreds of millions of

people in the world affected by rare diseases and other high-need

conditions, and who lack effective therapies to live their lives to the

fullest.

www.shire.com

This announcement is distributed by Nasdaq Corporate Solutions on behalf

of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Shire plc via Globenewswire

(END) Dow Jones Newswires

October 12, 2017 07:15 ET (11:15 GMT)